Lisa Millgård Sagberg1, Asgeir S Jakola, Ole Solheim. 1. Department of Neuroscience, Norwegian University of Science and Technology, 7491, Trondheim, Norway, lisa.millgard.sagberg@ntnu.no.
Abstract
PURPOSE: To evaluate the responsiveness of EQ-5D 3L in patients undergoing intracranial glioma surgery and estimate the minimal clinically important difference (MCID). MATERIALS AND METHODS: EQ-5D 3L index values from 164 patients who underwent glioma surgery in the period 2007-2012 were analysed. Responsiveness and MCID were estimated using a combination of distribution-based and anchor-based methods. Karnofsky performance status served as an anchor. RESULTS: Patients who improved functionally did not report significantly higher EQ-5D 3L scores post operatively with a standardized response mean (SRM) of 0.04 (p = 0.13). Patients who deteriorated functionally reported significantly lower EQ-5D 3L scores post operatively with a SRM of 0.72 (p < 0.001). With different approaches, we determined a range of MCID values from 0.13 to 0.15. CONCLUSIONS: EQ-5D 3L is responsive to changes when glioma patients are deteriorating functionally after surgery but not responsive when the patients are improving. The MCID values for EQ-5D 3L in glioma surgery seem higher than reported MCID values for other types of cancers.
PURPOSE: To evaluate the responsiveness of EQ-5D 3L in patients undergoing intracranial glioma surgery and estimate the minimal clinically important difference (MCID). MATERIALS AND METHODS: EQ-5D 3L index values from 164 patients who underwent glioma surgery in the period 2007-2012 were analysed. Responsiveness and MCID were estimated using a combination of distribution-based and anchor-based methods. Karnofsky performance status served as an anchor. RESULTS:Patients who improved functionally did not report significantly higher EQ-5D 3L scores post operatively with a standardized response mean (SRM) of 0.04 (p = 0.13). Patients who deteriorated functionally reported significantly lower EQ-5D 3L scores post operatively with a SRM of 0.72 (p < 0.001). With different approaches, we determined a range of MCID values from 0.13 to 0.15. CONCLUSIONS: EQ-5D 3L is responsive to changes when gliomapatients are deteriorating functionally after surgery but not responsive when the patients are improving. The MCID values for EQ-5D 3L in glioma surgery seem higher than reported MCID values for other types of cancers.
Authors: Edward F Chang; Matthew B Potts; G Evren Keles; Kathleen R Lamborn; Susan M Chang; Nicholas M Barbaro; Mitchel S Berger Journal: J Neurosurg Date: 2008-02 Impact factor: 5.115
Authors: Amir H Zamanipoor Najafabadi; Marthe C M Peeters; Linda Dirven; Daniel J Lobatto; Justus L Groen; Marieke L D Broekman; Saskia M Peerdeman; Wilo C Peul; Martin J B Taphoorn; Wouter R van Furth Journal: Neuro Oncol Date: 2017-07-01 Impact factor: 12.300
Authors: Isacco Montroni; Giampaolo Ugolini; Nicole M Saur; Siri Rostoft; Antonino Spinelli; Barbara L Van Leeuwen; Nicola De Liguori Carino; Federico Ghignone; Michael T Jaklitsch; Ponnandai Somasundar; Anna Garutti; Chiara Zingaretti; Flavia Foca; Bernadette Vertogen; Oriana Nanni; Steven D Wexner; Riccardo A Audisio Journal: J Natl Cancer Inst Date: 2022-07-11 Impact factor: 11.816
Authors: Ahmad Ousmen; Célia Touraine; Nina Deliu; Francesco Cottone; Franck Bonnetain; Fabio Efficace; Anne Brédart; Caroline Mollevi; Amélie Anota Journal: Health Qual Life Outcomes Date: 2018-12-11 Impact factor: 3.186